Impressive Results With Daratumumab Plus Lenalidomide/Dexamethasone in Multiple Myeloma - The ASCO Post
The Evolving Clinical and Pharmacoeconomic Impact of Isatuximab in Multiple Myeloma Management | Value-Based Cancer Care
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment | Leukemia
APOLLO Study | Int'l Myeloma Foundation
Omnihealth Practice | APOLLO: Phase 3 randomized study of subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials | Scientific Reports
Daratumumab and hyaluronidase-fihj (Darzalex Faspro) Drug Info
Pharmaceuticals | Free Full-Text | Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial - The Lancet Oncology
Multiple Myeloma Support + Trials
Daratumumab regimen extends PFS among certain patients with relapsed or refractory myeloma
Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement - Justin R Arnall, Saad Z Usmani, Hawawu
Newly Diagnosed: D + VTD Treatment | DARZALEX® IV (daratumumab)
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial - The
Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma - Transplantation ...
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse | Leukemia
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial - The Lancet Oncology
Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients - ScienceDirect
Subcutaneous daratumumab plus pomalidomide-dexamethasone: an effective treatment option for MM - BJH
Daratumumab Alone or in Combination with Lenalidomide/Dexamethasone or Pomalidomide/Dexamethasone for Relapsed/Refractory MM | Research To Practice
APOLLO trial results: Addition of daratumumab to pomalidomide + dexamethasone in relapsed/refractory multiple myeloma
APOLLO trial results: Addition of daratumumab to pomalidomide + dexamethasone in relapsed/refractory multiple myeloma
Daratumumab Re-Treatment Patterns. DPd: daratumumab, pomalidomide, and... | Download Scientific Diagram
Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma - Clinical Lymphoma, Myeloma and Leukemia
Subcutaneous daratumumab plus pomalidomide and dexamethasone in R/R MM - Medical Conferences
